Literature DB >> 33677403

A systematic review of adults with Dravet syndrome.

Arunan Selvarajah1, Quratulain Zulfiqar-Ali2, Paula Marques3, Marlene Rong1, Danielle M Andrade4.   

Abstract

Dravet Syndrome (DS) is a rare and severe infantile-onset epileptic encephalopathy. DS research focuses mainly on children. We did a systematic review, completed on January 18th, 2021, examining the number of clinical DS studies. We show that there are 208 studies on children exclusively, 28 studies on adults exclusively, and 116 studies involving adults and children combined. This 7:1 ratio of children to adult studies exclusively shows the dearth of research that addresses long-term natural history of DS into adulthood. Through this systematic review, we examine the most up-to-date information in DS adults as it pertains to seizures, electroencephalogram, imaging, treatment, motor abnormalities, cognitive and social behavior outcomes, cardiac abnormalities, sleep disturbances, diagnosis in adults, and mortality. Overall, the frequency of seizures increases in the first decade of life and then myoclonic, atypical absences and focal seizures with impaired awareness tend to decrease in frequency or even disappear in adulthood. Adults tend to have a notable reduction in status epilepticus, especially after 30 years of age. Parkinsonian features were seen in patients as young as 19 years old and are more severe in older patients, suggesting a progression of the parkinsonian symptoms. In adulthood, patients continue to present with behavior problems, associated with a lower health-related quality of life. The leading reported cause of death in DS adults is Sudden Unexpected Death in Epilepsy (SUDEP). Further studies in older adults are needed to understand the long-term outcomes of patients with DS.
Copyright © 2021 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adult; Dravet syndrome; Natural history; Parkinsonism; SCN1A; SUDEP; Severe myoclonic epilepsy of infancy; Systematic review

Year:  2021        PMID: 33677403     DOI: 10.1016/j.seizure.2021.02.025

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  9 in total

1.  Stiripentol Enteric Solid Dispersion-Loaded Effervescent Tablets: Enhanced Dissolution, Stability, and Absorption.

Authors:  Ying Wang; Siyuan Xu; Ziyue Xiao; Yuxin Jiang; Qi Jiang; Jun Li; Wei He
Journal:  AAPS PharmSciTech       Date:  2022-05-10       Impact factor: 3.246

2.  Progressive Worsening of Gait and Motor Abnormalities in Older Adults With Dravet Syndrome.

Authors:  Arunan Selvarajah; Carolina Gorodetsky; Paula Marques; Quratulain Zulfiqar Ali; Anne T Berg; Alfonso Fasano; Danielle M Andrade
Journal:  Neurology       Date:  2022-04-13       Impact factor: 11.800

3.  COVID-19 vaccine in patients with Dravet syndrome: Observations and real-world experiences.

Authors:  Veronica Hood; Anne T Berg; Kelly G Knupp; Sookyong Koh; Linda Laux; Mary Anne Meskis; Quratulain Zulfiqar-Ali; M Scott Perry; Ingrid E Scheffer; Joseph Sullivan; Elaine Wirrell; Danielle M Andrade
Journal:  Epilepsia       Date:  2022-04-20       Impact factor: 6.740

Review 4.  SCN1A Mutation-Beyond Dravet Syndrome: A Systematic Review and Narrative Synthesis.

Authors:  Jiangwei Ding; Xinxiao Li; Haiyan Tian; Lei Wang; Baorui Guo; Yangyang Wang; Wenchao Li; Feng Wang; Tao Sun
Journal:  Front Neurol       Date:  2021-12-24       Impact factor: 4.003

Review 5.  Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.

Authors:  Elena Cardenal-Muñoz; Stéphane Auvin; Vicente Villanueva; J Helen Cross; Sameer M Zuberi; Lieven Lagae; José Ángel Aibar
Journal:  Epilepsia Open       Date:  2021-12-19

6.  A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-02-14       Impact factor: 5.749

7.  Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis.

Authors:  Jianhua Wu; Liu Zhang; Xi Zhou; Jiajun Wang; Xiangyi Zheng; Hankun Hu; Dongfang Wu
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

Review 8.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

9.  Antiepileptic Stiripentol May Influence Bones.

Authors:  Agnieszka Matuszewska; Beata Nowak; Anna Nikodem; Anna Merwid-Ląd; Benita Wiatrak; Tomasz Tomkalski; Diana Jędrzejuk; Ewa Szeląg; Tomasz Sozański; Maciej Danielewski; Paulina Jawień; Ireneusz Ceremuga; Marta Szandruk-Bender; Marek Bolanowski; Jarosław Filipiak; Adam Szeląg
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.